Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

Fabio Rocha Formiga, Roger Leblanc, Juliana de Souza Rebouças, Leonardo Paiva Farias, Ronaldo Nascimento de Oliveira, Lindomar Pena

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.

Original languageEnglish (US)
Pages (from-to)758-761
Number of pages4
JournalJournal of Controlled Release
StatePublished - Jan 10 2021

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Ivermectin: an award-winning drug with expected antiviral activity against COVID-19'. Together they form a unique fingerprint.

Cite this